Global Pharmacovigilance Market Set To Grow To $11.5bn By 2023

03 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Pharmacovigilance Market Forecast 2018-2028: US, Japan, Germany, the UK, France, Italy, Spain, Brazil, Russia, India, China, South Korea, National Pharmacovigilance Systems, Leading Companies, Trends

This report covers trends in the pharmacovigilance market from 2017. It discusses those operations, regulations for drug monitoring, and the future of drug safety. It analyses pharmacovigilance from historical events to the future, predicting how post-marketing drug assessments will develop, and revenues from those services expand. National regulatory authorities are moving towards risk-benefit management planning to assess drug safety, putting greater pressure on pre-marketing safety and efficacy data. Needs for post-marketing surveillance have also increased, with active and intensive monitoring being introduced into adverse drug reaction reporting systems.

The lead analyst of the report commented “Using pharmacogenomics to establish safety profiles for drugs potentially represents the most significant steps in pharmacovigilance over the next decade. The number of clinical genetic tests being designed and produced is increasing, as is the volume of pharmacogenomic data submitted to regulators. As more is understood of the role of genetic variations in drug safety, regulators will demand more pharmacogenomic data during the approval application process for inclusion in risk management strategies.

The discovery and use of biomarkers, either during drug development or the early post-marketing phase, can accelerate drug approval or expansion of approval. New classification methods for adverse reactions will help to establish ADR mechanisms in relation to the genetic characteristic of the patient. This will, in a similar way to the discovery of biomarkers, help mark out subpopulations for whom the drug is an inappropriate. Further development of the system will eventually lead to its adoption as a common method of classification globally.”

Leading companies featured in the report include Accenture PLC, Cognizant Technology Solutions Corporation, Tata Consultancy Services (TCS), Capgemini SE, Tech Mahindra Limited, Infosys Limited (Infosys), Wipro Limited (Wipro), Oracle Corporation (Oracle), Bristol-Myers Squibb Company, HCL Technologies Ltd., Olympus Corporation
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

“Global Ophthalmic Equipment market set to grow to $75bn by 2024” says new Visiongain report

here is a growing demand for ophthalmic equipment such as vision care products and ophthalmology surgical devices, mainly due to the increasing incidence of myopia across the world.

03 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever